表纸
市场调查报告书

传染病生物标志物检测全球市场(2020-2030):竞争环境,市场分析,增长预测

Global Infectious Disease Biomarker Testing Market: Focus on Product Type, Technology, Pathogen, Application, End-user, 5 Regional Data, 15 Countries' Data, and Competitive Landscape - Analysis and Forecast, 2020-2030

出版商 BIS Research Inc. 商品编码 951625
出版日期 内容资讯 英文 352 Pages
商品交期: 最快1-2个工作天内
价格
传染病生物标志物检测全球市场(2020-2030):竞争环境,市场分析,增长预测 Global Infectious Disease Biomarker Testing Market: Focus on Product Type, Technology, Pathogen, Application, End-user, 5 Regional Data, 15 Countries' Data, and Competitive Landscape - Analysis and Forecast, 2020-2030
出版日期: 2020年07月29日内容资讯: 英文 352 Pages
简介

全球传染病生物标志物测试市场预计将以14.48%的复合年增长率增长,到2030年将达到250亿美元。新型冠状病毒传染病(COVID-19)和其他传染病的大流行,生物标志物鉴定市场的发展,分子技术的发展,生物标志物测试平台的快速发展,其速度和靈敏度得到了提高合规性和用于研发的大规模外部资金等因素正在推动该市场的增长。

该报告调查了全球传染病生物标志物检测市场,定义和概述了市场,分析了COVID-19和其他市场影响因素,市场规模趋势/预测,产品/应用/技术。总结了病原体,最终用户,地区/主要国家/地区和主要公司的概况等各种类别的细分。

第1章产品定义

第2章调查范围

第3章调查方法

第4章市场概述

  • 简介
  • 生物标志物的重要性
  • 用于临床的生物标志物类型
  • 传染病生物标志物检测方法
  • 传染病的POC测试
  • 市场上有传染病生物标志物测试
  • 世界足迹

第5章市场动态

  • 概述
  • 影响分析
  • 市场增长因素
  • 市场约束因素
  • 市场机会

第6章产业分析

  • 行业趋势
  • COVID-19的影响
  • 与传染病研究有关的问题

第7章竞争情况

  • 概述
  • 主要发展/战略
  • 市场份额分析

第8章按产品进行的市场分析和预测

  • 概述
  • 测定
  • 平台

第9章按应用进行市场分析和预测

  • 概述
  • 呼吸道感染
  • 性传播疾病
  • 血流/医院感染
  • 尿路感染
  • 胃肠道感染
  • 中枢神经系统感染
  • 其他

第10章按技术进行市场分析和预测

  • 概述
  • PCR
  • NGS
  • ELISA/EIA
  • IHC
  • ISH

第11章按病原体进行市场分析和预测

  • 概述
  • 病毒
  • 细菌
  • 其他

第12章最终用户的市场分析和预测

  • 概述
  • 医院和诊所
  • 诊断中心
  • 调查
  • 其他

第13章按地区和主要国家进行的市场分析和预测

  • 概述
  • 北美
  • 欧洲
  • 亚太地区
  • 其他地区

第14章公司简介

  • Abacus Diagnostica Oy
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • ALPCO
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd
  • Hologic, Inc.
  • PerkinElmer, Inc.
  • QIAGEN N.V.
  • Quest Diagnostics Incorporated
  • Siemens Healthineers AG
  • Thermo Fisher Scientific, Inc.
目录
Product Code: BHL0945SA

Global Infectious Disease Biomarker Testing Market to Reach $25.01 Billion by 2030

Market Report Coverage - Infectious Disease Biomarker Testing

Market Segmentation

  • By Product - Assays and Platforms
  • By Technology - PCR, NGS, ELISA or EIA, IHC, ISH, and Others
  • By Application - Respiratory Infection, Sexually Transmitted Infection, Bloodstream and Hospital Acquired Infection, Urinary Tract Infection, Gastro-Intestinal Infection, CNS Infection, and Others
  • By End User - Hospitals and Clinics, Diagnostic Centers, Academic Research Institutes, and Others
  • By Pathogen - Bacteria, Virus, Fungi, and Others

Regional Segmentation

  • North America - U.S., Canada
  • Europe - Germany, U.K., France, Italy, Switzerland, Spain, Netherlands, and Rest-of-Europe
  • Asia-Pacific - China, Australia, Japan, India, South Korea, Singapore, and Rest-of-Asia-Pacific
  • Rest-of-the-World - Latin America and Middle East and Africa

Growth Drivers

  • Increasing Burden of Pervasively Growing Rate of Infectious Diseases
  • Advancements in Molecular Techniques and Elevated Demand for Biomarker Tests in NGS
  • Boosting Research and Increasing Funding Activities for Clinical Biomarkers
  • Booming Clinical Diagnostic Test Market and Rising Uptake of Biomarker Tests Among Healthcare Professionals

Market Challenges

  • Poorly Suited Reimbursement Policies
  • High Capital Investments and Lack of Intricate Testing Centres
  • Uncertain Regulatory Framework Delaying Tests Approval

Market Opportunities

  • Untapped Potential of Emerging Nations Creating Vast Opportunities
  • Rapid Technological Advancements and Inclination Towards Automation
  • Widespread Emergence of CROs Specializing on Infectious Diseases

Key Companies Profiled

Abacus Diagnostica Oy, ALPCO, Abbott Laboratories, Agilent Technologies, Inc., Becton, Dickinson and Company, bioMerieux SA, Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd, Hologic, Inc., PerkinElmer, Inc., Qiagen N.V., Quest Diagnostics Incorporated, Siemens Healthineers AG, and Thermo Fisher Scientific, Inc.

Key Questions Answered in this Report:

  • What is a biomarker and what is the importance of biomarker testing?
  • What are the different biomarker testing approaches for infectious diseases? What are utilities associated with clinical biomarkers and what are the different types of biomarker available for commercial application?
  • What are the major advancements in infectious disease biomarker testing market? What are the key trends of the global infectious disease biomarker testing market? How is the market evolving and what is its future scope?
  • What is the market scenario and growth potential of different regions of the world, including North America, Europe, Asia-Pacific, and Rest-of-the-World?
  • What are the major drivers, challenges, and opportunities of the global infectious disease biomarker testing market?
  • What is the impact of the novel corona virus outbreak on the global infectious disease biomarker testing market? How is COVID19 pandemic expected to influence the market in the upcoming years?
  • What are the major key players of the global infectious disease biomarker testing market? How much market share does each of these players occupy in the market in 2019? Which companies are anticipated to be highly disruptive in the future and why?
  • What are the key developmental strategies implemented by the key players of the global infectious disease biomarker testing market to sustain the competition of the market? What is the percentage share of each of the key players in different key developmental strategies?
  • What was the market size of the global infectious disease biomarker testing market in 2019 and what is the market size anticipated to be in 2030? What is the expected growth rate of the global infectious disease biomarker testing market during the period between 2020 and 2030?
  • What is the global market size of different types of products of the global infectious disease biomarker testing market in 2019? What are the key trends of the market with respect to different platforms and assays and which product is expected to dominate the market in 2030?
  • What are the different technologies supported by the biomarker testing products? Which technology type dominated the market in 2019 and is expected to dominate in 2030?
  • What are the different applications associated with infectious disease biomarker testing? What was the contribution of each of the application areas in the global infectious disease biomarker testing market for the time period between 2019 and 2030?
  • How is the global infectious disease biomarker testing market segmented based on pathogen type? Which pathogen is currently leading the market and why? Which pathogen type is expected to lead the market during the forecast?
  • What are the different end-users of the global infectious disease biomarker testing market? Which end-user type is the major contributor of revenue in the market?
  • Which region is expected to contribute the highest sales in the global infectious disease biomarker testing market during the period between 2019 and 2030? What are the leading countries of different regions that contribute significantly toward the growth of the global infectious disease biomarker testing market?

Market Overview

Increasing prevalence of emerging and re-emerging infectious diseases continue to be instrumental in escalating the economic, social, and clinical burden across the globe. In 2016, the World Health Organization (WHO) placed three infectious diseases among the top ten causes of death. It included lower respiratory infections, diarrheal diseases, and tuberculosis, accounting for 3.0 million deaths, 1.4 million deaths, and 1.3 million deaths, respectively. Despite the immense effort across the world to control the occurrence of infectious diseases with the ever-evolving healthcare systems, the world continues to be confronted by infectious disease threats, most often in the form of epidemics, pandemics, or outbreaks. Thus, the soaring demand for better treatment outcome is leading to an ascending need for preventive, precise healthcare, and tailored medication. Diagnosis, being the first step to treatment, has always been an active area of investment owing to the increasing prevalence of infectious diseases. The field of diagnostics has undergone rapid transformation over the decades with the development and introduction of wide variety of products that aid in the diagnosis, screening, and prognosis of diseases. As a major segment of diagnostics, biomarker testing has evolved as one of the most transformative and dynamic areas of clinical diagnostics that continue to revolutionize healthcare across a broad continuum of infectious diseases. Owing to the recent COVID-19 outbreak, the global infectious disease biomarker testing market is expected to grow dynamically with a robust growth rate.

Our healthcare experts have found biomarker testing industry for infectious diseases to be one of the most rapidly evolving markets, and the global market for infectious disease biomarker testing market is predicted to grow at a CAGR of 14.48% during the forecast period of 2020-2030. This growth of the global infectious disease biomarker testing market is primarily attributed to the major drivers that include highly increasing global prevalence of infectious diseases, growth in the biomarker identification market and advancements in molecular techniques, rapid advances in biomarker testing platforms with improved speed, sensitivity, and patient compliance, and significant external funding for executing research and development exercises.

The market is expected to grow at a significant growth rate due to the opportunities that lie within its domain, which include a massive scope for adoption of infectious disease biomarker testing products in emerging nations, increase in the adoption of automation & multiplexing of technologies, and rise in number of CROs offering disease testing services. However, there are certain challenges that tends to restrain its growth. These challenges include an uncertain reimbursement scenario, a lack of high-complexity testing centers and complex regulatory frameworks delaying the approval of new tests. However, with increasing support from the government across all the countries of the world to uplift patient care and improve healthcare infrastructure, the infectious disease biomarker testing market is expected to grow vigorously. Entry of new companies in the market and launch of new biomarker testing product lines are further expected to boost its growth in the upcoming years.

Within the research report, the market is segmented on the basis of product, technology, pathogen, application, end user, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the adoption of biomarker testing products for different application areas of infectious diseases on the global level has created a buzz among companies to invest significantly in global infectious disease biomarker testing market. The market is highly competitive, with the presence of various juggernauts such as F. Hoffmann-La Roche Ltd, Qiagen N.V., Siemens Healthineers AG, Beckman Coulter, Inc., Becton, Dickinson and Company, Abbott Laboratories, Thermo Fisher Scientific Inc, and bioMerieux SA, among others. With the increasing demand for faster and accurate diagnostic measures, companies have the opportunity to expand their product portfolios in the market through different strategic approaches. Some of the common strategies followed by the contributors are partnership and alliances (collaborations and joint ventures), acquisitions, product offerings (launches), product approvals, and business expansion activities.

Table of Contents

1 Product Definition

  • 1.1 Inclusion and Exclusion

2 Scope of the Work

  • 2.1 Overview: Report Scope
  • 2.2 Segmentation of the Global Infectious Disease Biomarker Testing Market
  • 2.3 Assumptions and Limitations
  • 2.4 Key Questions Answered in the Report
  • 2.5 Base Year and Forecast Period

3 Research Methodology

  • 3.1 Overview: Report Methodology

4 Market Overview

  • 4.1 Introduction
  • 4.2 Importance of Biomarkers
  • 4.3 Types of Biomarkers Used in Clinical Applications
    • 4.3.1 Biomarkers for Risk Prediction:
    • 4.3.2 Biomarker for Diseases:
  • 4.4 Infectious Disease Biomarker Testing Approach
  • 4.5 Point-of-Care (POC) Testing for Infectious Diseases
  • 4.6 Infectious Disease Biomarker Tests Available in the Market
  • 4.7 Global Footprint

5 Market Dynamics

  • 5.1 Overview
  • 5.2 Impact Analysis
  • 5.3 Market Drivers
    • 5.3.1 Increasing Burden of Pervasively Growing Rate of Infectious Diseases
    • 5.3.2 Advancements in Molecular Techniques and Increased Investment on Biomarker Testing by NGS Players
    • 5.3.3 Boosting Research and Increasing Funding Activities for Clinical Biomarkers
    • 5.3.4 Booming Clinical Diagnostic Test Market and Rising Uptake of Biomarker Tests Among Healthcare Professionals
  • 5.4 Market Restraints
    • 5.4.1 Poorly Suited Reimbursement Policies
    • 5.4.2 High Capital Investments and Lack of Intricate Testing Centers
    • 5.4.3 Uncertain Regulatory Framework Delaying Tests Approval
  • 5.5 Market Opportunities
    • 5.5.1 Untapped Potential of Emerging Nations Creating Vast Opportunities
    • 5.5.2 Rapid Technological Advancements and Inclination Toward Automation
    • 5.5.3 Widespread Emergence of CROs Specializing on Infectious Diseases

6 Industry Insights

  • 6.1 Industry Trends
  • 6.2 Effect of Pandemics and Epidemics on the Infectious Disease Biomarker Testing Market
  • 6.3 Effect of COVID-19 on the Global Healthcare Industry
    • 6.3.1 Negative Impact on Non-Communicable Disease Sectors
    • 6.3.2 Positive Impact on Infectious Disease Diagnostic Sector
  • 6.4 COVID-19 Impact on Global Infectious Disease Biomarker Testing Market
    • 6.4.1 Situation Analysis: Pre-COVID-19 Outbreak, During COVID-19 Outbreak and Post COVID-19 Outbreak
    • 6.4.2 Impact on Respiratory Infection Segment
  • 6.5 Challenges Associated with Infectious Disease Research

7 Competitive Landscape

  • 7.1 Overview
  • 7.2 Key Developments and Strategies
    • 7.2.1 Product Approval
    • 7.2.2 New Offerings
    • 7.2.3 Partnerships and Alliances
    • 7.2.4 M&A Activities
    • 7.2.5 Others
  • 7.3 Market Share Analysis
  • 7.4 Growth Share Analysis (Opportunity Mapping)
    • 7.4.1 By Application
    • 7.4.2 By Technology

8 Global Infectious Disease Biomarker Testing Market (by Product)

  • 8.1 Overview
  • 8.2 Assays
    • 8.2.1 Overview
    • 8.2.2 Market Scenario
  • 8.3 Platforms
    • 8.3.1 Overview
    • 8.3.2 Market Scenario

9 Global Infectious Disease Biomarker Testing Market (by Application)

  • 9.1 Overview
  • 9.2 Respiratory Infection
    • 9.2.1 Overview
    • 9.2.2 Common Pathogens Associated with Respiratory Infection
    • 9.2.3 Market Scenario
  • 9.3 Sexually Transmitted Infection
    • 9.3.1 Overview
    • 9.3.2 Common Pathogens Associated with Sexually Transmitted Infection
    • 9.3.3 Market Scenario
  • 9.4 Bloodstream and Hospital-Acquired Infection
    • 9.4.1 Overview
    • 9.4.2 Common Pathogens Associated with Bloodstream and Hospital Acquired Infections
    • 9.4.3 Market Scenario
  • 9.5 Urinary Tract Infection
    • 9.5.1 Overview
    • 9.5.2 Common Causes of Urinary tract infection (UTI)
    • 9.5.3 Market Scenario
  • 9.6 Gastro-Intestinal Infection
    • 9.6.1 Overview
    • 9.6.2 Common Causes of Gastro-Intestinal (GI) Infection
    • 9.6.3 Market Scenario
  • 9.7 Central Nervous System Infection
    • 9.7.1 Overview
    • 9.7.2 Common Causes of CNS Infection
    • 9.7.3 Market Scenario
  • 9.8 Others

10 Global Infectious Disease Biomarker Testing Market (by Technology)

  • 10.1 Overview
  • 10.2 PCR
    • 10.2.1 Overview
    • 10.2.2 Market Scenario
  • 10.3 NGS
    • 10.3.1 Overview
    • 10.3.2 Market Scenario
  • 10.4 ELISA or EIA
    • 10.4.1 Overview
    • 10.4.2 Market Scenario
  • 10.5 IHC
    • 10.5.1 Overview
    • 10.5.2 Market Scenario
  • 10.6 ISH
    • 10.6.1 Overview
    • 10.6.2 Market Scenario
  • 10.7 Others

11 Global Infectious Disease Biomarker Testing Market (by Pathogen)

  • 11.1 Overview
  • 11.2 Virus
    • 11.2.1 Overview
    • 11.2.2 Examples of Common Viral Infections
    • 11.2.3 Market Scenario
    • 11.2.4 Market Segmentation by Different Viral Infection
      • 11.2.4.1 Influenza
      • 11.2.4.2 HIV-AIDS
      • 11.2.4.3 Hepatitis
      • 11.2.4.4 HPV
      • 11.2.4.5 Other Viruses
  • 11.3 Bacteria
    • 11.3.1 Overview
    • 11.3.2 Examples of Common Viral Infections
    • 11.3.3 Market Scenario
    • 11.3.4 Market Segmentation by Different Bacterial Infection
      • 11.3.4.1 Hospital-Acquired Infection
      • 11.3.4.2 Tuberculosis
      • 11.3.4.3 CT/NG
      • 11.3.4.4 Other Bacteria
  • 11.4 Others

12 Global Infectious Disease Biomarker Testing Market (by End User)

  • 12.1 Overview
  • 12.2 Hospitals and Clinics
  • 12.3 Diagnostic Centers
  • 12.4 Research Laboratories
  • 12.5 Other End Users

13 Global Infectious Disease Biomarker Testing Market (by Region)

  • 13.1 Overview
  • 13.2 North America
    • 13.2.1 Overview
    • 13.2.2 U.S.
    • 13.2.3 Canada
  • 13.3 Europe
    • 13.3.1 Overview
    • 13.3.2 Germany
    • 13.3.3 U.K.
    • 13.3.4 France
    • 13.3.5 Italy
    • 13.3.6 Spain
    • 13.3.7 Switzerland
    • 13.3.8 Netherlands
    • 13.3.9 Rest-of-Europe
  • 13.4 Asia-Pacific
    • 13.4.1 Overview
    • 13.4.2 China
    • 13.4.3 Japan
    • 13.4.4 India
    • 13.4.5 Australia
    • 13.4.6 Singapore
    • 13.4.7 South Korea
    • 13.4.8 Rest-of-Asia-Pacific
  • 13.5 Rest-of-the-World
    • 13.5.1 Overview
    • 13.5.2 Latin America
    • 13.5.3 Middle East and Africa

14 Company Profiles

  • 14.1 Overview
  • 14.2 Abacus Diagnostica Oy
    • 14.2.1 Company Overview
    • 14.2.2 Role of Abacus Diagnostica Oy in the Global Infectious Disease Biomarker Testing Market
    • 14.2.3 SWOT Analysis
  • 14.3 Abbott Laboratories
    • 14.3.1 Company Overview
    • 14.3.2 Role of Abbott Laboratories in the Global Infectious Disease Biomarker Testing Market
    • 14.3.3 Financials
    • 14.3.4 Key Insights About Financial Health of the Company
    • 14.3.5 SWOT Analysis
  • 14.4 Agilent Technologies, Inc.
    • 14.4.1 Company Overview
    • 14.4.2 Role of Agilent Technologies, Inc. in the Global Infectious Disease Biomarker Testing Market
    • 14.4.3 Financials
    • 14.4.4 Key Insights About Financial Health of the Company
    • 14.4.5 SWOT Analysis
  • 14.5 ALPCO
    • 14.5.1 Company Overview
    • 14.5.2 Role of ALPCO in the Global Infectious Disease Biomarker Testing Market
    • 14.5.3 SWOT Analysis
  • 14.6 Becton, Dickinson and Company
    • 14.6.1 Company Overview
    • 14.6.2 Role of Becton, Dickinson and Company in the Global Infectious Disease Biomarker Testing Market
    • 14.6.3 Financials
    • 14.6.4 Key Insights About Financial Health of the Company
    • 14.6.5 SWOT Analysis
  • 14.7 bioMerieux SA
    • 14.7.1 Company Overview
    • 14.7.2 Role of bioMerieux SA in the Global Infectious Disease Biomarker Testing Market
    • 14.7.3 Financials
    • 14.7.4 Key Insights About Financial Health of the Company
    • 14.7.5 SWOT Analysis
  • 14.8 Bio-Rad Laboratories, Inc.
    • 14.8.1 Company Overview
    • 14.8.2 Role of Bio-Rad Laboratories, Inc. in the Global Infectious Disease Biomarker Testing Market
    • 14.8.3 Financials
    • 14.8.4 Key Insights About Financial Health of the Company
    • 14.8.5 SWOT Analysis
  • 14.9 Danaher Corporation
    • 14.9.1 Company Overview
    • 14.9.2 Role of Danaher Corporation in the Global Infectious Disease Biomarker Testing Market
    • 14.9.3 Financials
    • 14.9.4 Key Insights About Financial Health of the Company
    • 14.9.5 SWOT Analysis
  • 14.1 F. Hoffmann-La Roche Ltd
    • 14.10.1 Company Overview
    • 14.10.2 Role of F. Hoffmann-La Roche Ltd in the Global Infectious Disease Biomarker Testing Market
    • 14.10.3 Financials
    • 14.10.4 Key Insights About Financial Health of the Company
    • 14.10.5 SWOT Analysis
  • 14.11 Hologic, Inc.
    • 14.11.1 Company Overview
    • 14.11.2 Role of Hologic, Inc. in the Global Infectious Disease Biomarker Testing Market
    • 14.11.3 Financials
    • 14.11.4 Key Insights About Financial Health of the Company
    • 14.11.5 SWOT Analysis
  • 14.12 PerkinElmer, Inc.
    • 14.12.1 Company Overview
    • 14.12.2 Role of PerkinElmer, Inc. in the Global Infectious Disease Biomarker Testing Market
    • 14.12.3 Financials
    • 14.12.4 Key Insights About Financial Health of the Company
    • 14.12.5 SWOT Analysis
  • 14.13 QIAGEN N.V.
    • 14.13.1 Company Overview
    • 14.13.2 Role of QIAGEN N.V. in the Global Infectious Disease Biomarker Testing Market
    • 14.13.3 Financials
    • 14.13.4 Key Insights About Financial Health of the Company
    • 14.13.5 SWOT Analysis
  • 14.14 Quest Diagnostics Incorporated
    • 14.14.1 Company Overview
    • 14.14.2 Role of Quest Diagnostics Incorporated in the Global Infectious Disease Biomarker Testing Market
    • 14.14.3 Financials
    • 14.14.4 SWOT Analysis
  • 14.15 Siemens Healthineers AG
    • 14.15.1 Company Overview
    • 14.15.2 Role of Siemens Healthineers AG in the Global Infectious Disease Biomarker Testing Market
    • 14.15.3 Financials
    • 14.15.4 Key Insights About Financial Health of the Company
    • 14.15.5 SWOT Analysis
  • 14.16 Thermo Fisher Scientific, Inc.
    • 14.16.1 Company Overview
    • 14.16.2 Role of Thermo Fisher Scientific, Inc. in the Global Infectious Disease Biomarker Testing Market
    • 14.16.3 Financials
    • 14.16.4 Key Insights About Financial Health of the Company
    • 14.16.5 SWOT Analysis

List of Tables

  • Table 1: Prominent Outbreaks, Epidemics, and Pandemics of Recent Decades
  • Table 2: Leading Segments of the Global Infectious Disease Biomarker Testing Market, 2019 and 2030
  • Table 4.1: Advantages and Disadvantages of Biomarkers in Diagnostic Tests
  • Table 4.2: Key Commercialized Products Offered by Major Market Players
  • Table 5.1: Impact Analysis of Market Drivers
  • Table 5.2: Impact Analysis of Market Restraints
  • Table 5.3: Number of Deaths by Cause, 2017
  • Table 6.1: Impact of COVID-19 on Different Countries
  • Table 6.2: Tests Conducted per new Confirmed Case of COVID-19
  • Table 6.3: COVID-19 Related Product Offering by Major Players
  • Table 8.1: Key Biomarker Testing Assays Offered by Major Market Players
  • Table 8.2: Key Biomarker Testing Assays Offered by Major Market Players
  • Table 9.1: Pathogens Responsible for Different Respiratory Infections
  • Table 9.2: Key Biomarker Testing Products for Respiratory Infection Offered by Major Market Players
  • Table 9.3: Key Biomarker Testing Products for Sexually Transmitted Infection Offered by Major Market Players
  • Table 9.4: Key Biomarker Testing Products for Bloodstream and Hospital Acquired Infection Offered by Major Market Players
  • Table 9.5: Key Biomarker Testing Products for Urinary Tract Infection Offered by Major Market Players
  • Table 9.6: Key Biomarker Testing Products for Gastro-Intestinal Infection Offered by Major Market Players
  • Table 9.7: Key Biomarker Testing Products for CNS Infection Offered by Major Market Players
  • Table 9.8: Key Biomarker Testing Products for other Infections Offered by Major Market Players
  • Table 10.1: Key PCR-based Biomarker Testing Products Offered by Major Market Players
  • Table 10.2: Key NGS-based Biomarker Testing Products Offered by Major Market Players
  • Table 10.3: Key ELISA-based Biomarker Testing Products Offered by Major Market Players
  • Table 10.4: Key IHC-based Biomarker Testing Products Offered by Major Market Players
  • Table 11.1: Key Biomarker Testing Products for Viral Infection Offered by Major Market Players
  • Table 11.2: Key Biomarker Testing Products for Bacterial Infection Offered by Major Market Players
  • Table 13.1: Projected 2030 Mortality and 10-Year Trends for Selected Infections, by Country Income Group

List of Figures

  • Figure 1: Global Infectious Disease Biomarker Testing Market (by Region), 2019 and 2030
  • Figure 2: Key Players of the Global Infectious Disease Biomarker Testing Market
  • Figure 3: Global Infectious Disease Biomarker Testing Market - Drivers, Challenges, and Opportunities
  • Figure 4: Impact of COVID-19 on the Growth of Global Infectious Disease Biomarker Testing Market, 2019-2025
  • Figure 5: Share of Key Developments and Strategies, January 2017-April 2020
  • Figure 6: Global Infectious Disease Biomarker Testing Market (by Product), 2019-2030
  • Figure 7: Global Infectious Disease Biomarker Testing Market (by Application), 2019-2030
  • Figure 8: Global Infectious Disease Biomarker Testing Market (by Technology), 2019-2030
  • Figure 9: Global Infectious Disease Biomarker Testing Market (by Pathogen), 2019-2030
  • Figure 10: Global Infectious Disease Biomarker Testing Market (by End User), 2019-2030
  • Figure 2.1: Global Infectious Disease Biomarker Testing Market Segmentation
  • Figure 3.1: Global Infectious Disease Biomarker Testing Market Research Methodology
  • Figure 3.2: Primary Research
  • Figure 3.3: Secondary Research
  • Figure 3.4: Data Triangulation
  • Figure 3.5: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 3.6: Top-Down Approach (Segment-Wise Analysis)
  • Figure 3.7: Assumptions and Limitations
  • Figure 4.1: Global Infectious Disease Biomarker Testing Market, with Y-o-Y, 2019-2030
  • Figure 6.1: Recent Pandemics/Epidemics
  • Figure 6.2: Impact of COVID-19 on the Growth of Global Infectious Disease Biomarker Testing Market, 2019-2030
  • Figure 6.3: Global Infectious Disease Biomarker Market Share (by Application), 2019 and 2020
  • Figure 7.1: Competitive Landscape (January 2017-April 2020)
  • Figure 7.2: Share of Key Developments and Strategies, January 2017-April 2020
  • Figure 7.3: Product Approvals (by Company), January 2017 and April 2020
  • Figure 7.4: New Offerings (by Company), January 2017 and April 2020
  • Figure 7.5: Partnerships and Alliances (by Company), January 2017 and April 2020
  • Figure 7.6: M & A Activities (by Company), January 2017 and April 2020
  • Figure 7.7: Market Share Analysis of Global Infectious Disease Biomarker Testing Market, 2018 and 2019
  • Figure 7.8: Growth Share Matrix for Global Infectious Disease Biomarker Testing Market (by Application), 2019-2030
  • Figure 7.9: Growth Share Matrix for Global Infectious Biomarker Testing Market (by Technology), 2019-2030
  • Figure 8.1: Global Infectious Disease Biomarker Testing Market Segmentation (by Product)
  • Figure 8.2: Global Infectious Disease Biomarker Testing Market (by Product), 2019-2030
  • Figure 8.3: General Workflow of a Molecular Diagnostic Kit
  • Figure 8.4: Global Infectious Disease Biomarker Testing Market for Assay, 2019-2030
  • Figure 8.5: Global Infectious Disease Biomarker Testing Market for Platforms, 2019-2030
  • Figure 9.1: Global Infectious Disease Biomarker Testing Market Segmentation (by Application)
  • Figure 9.2: Global Infectious Disease Biomarker Testing Market (by Application), 2019-2030
  • Figure 9.3: Global Infectious Disease Biomarker Testing Market for Respiratory Infection, 2019-2030
  • Figure 9.4: Global Infectious Disease Biomarker Testing Market for Sexually Transmitted Infection, 2019-2030
  • Figure 9.5: Global Infectious Disease Biomarker Testing Market for Bloodstream and Hospital Acquired Infections, 2019-2030
  • Figure 9.6: Global Infectious Disease Biomarker Testing Market for Urinary Tract Infections, 2019-2030
  • Figure 9.7: Global Infectious Disease Biomarker Testing Market for Gastro-Intestinal Infections, 2019-2030
  • Figure 9.8: Global Infectious Disease Biomarker Testing Market for CNS Infections, 2019-2030
  • Figure 9.9: Global Infectious Disease Biomarker Testing Market for Others, 2019-2030
  • Figure 10.1: Global Infectious Disease Biomarker Testing Market Segmentation (by Technology)
  • Figure 10.2: Global Infectious Disease Biomarker Testing Market (by Technology), 2019-2030
  • Figure 10.3: Global Infectious Disease Biomarker Testing Market for PCR, 2019-2030
  • Figure 10.4: Global Infectious Disease Biomarker Testing Market for NGS, 2019-2030
  • Figure 10.5: Global Infectious Disease Biomarker Testing Market for ELISA or EIA, 2019-2030
  • Figure 10.6: Global Infectious Disease Biomarker Testing Market for IHC, 2019-2030
  • Figure 10.7: Global Infectious Disease Biomarker Testing Market for ISH, 2019-2030
  • Figure 10.8: Global Infectious Disease Biomarker Testing Market for Others, 2019-2030
  • Figure 11.1: Global Infectious Disease Biomarker Testing Market Segmentation (by Pathogen)
  • Figure 11.2: Global Infectious Disease Biomarker Testing Market (by Pathogen), 2019-2030
  • Figure 11.3: Global Infectious Disease Biomarker Testing Market for Virus, 2019-2030
  • Figure 11.4: Global Biomarker Testing Market for Virus (by Viral Infection), 2019-2030
  • Figure 11.5: Global Infectious Disease Biomarker Testing Market for Influenza Virus, 2019-2030
  • Figure 11.6: Global Infectious Disease Biomarker Testing Market for HIV, 2019-2030
  • Figure 11.7: Global Infectious Disease Biomarker Testing Market for Hepatitis, 2019-2030
  • Figure 11.8: Global Infectious Disease Biomarker Testing Market for HIV, 2019-2030
  • Figure 11.9: Global Infectious Disease Biomarker Testing Market for Others, 2019-2030
  • Figure 11.10: Global Infectious Disease Biomarker Testing Market for Bacteria, 2019-2030
  • Figure 11.11: Global Biomarker Testing Market for Bacteria (by Bacteria Infection), 2019-2030
  • Figure 11.12: Global Infectious Disease Biomarker Testing Market for Hospital-Acquired Infection, 2019-2030
  • Figure 11.13: Global Infectious Disease Biomarker Testing Market for Tuberculosis, 2019-2030
  • Figure 11.14: Global Infectious Disease Biomarker Testing Market for CT/NG, 2019-2030
  • Figure 11.15: Global Infectious Disease Biomarker Testing Market for Others, 2019-2030
  • Figure 11.16: Global Infectious Disease Biomarker Testing Market for Others, 2019-2030
  • Figure 12.1: Global Infectious Disease Biomarker Testing Market Segmentation (by End User)
  • Figure 12.2: Global Infectious Disease Biomarker Testing Market (by End User), 2019-2030
  • Figure 12.3: Global Infectious Disease Biomarker Testing Market for Hospitals and Clinics, 2019-2030
  • Figure 12.4: Global Infectious Disease Biomarker Testing Market for Diagnostic Centers, 2019-2030
  • Figure 12.5: Global Infectious Disease Biomarker Testing Market for Research Laboratories, 2019-2030
  • Figure 12.6: Global Infectious Disease Biomarker Testing Market for Other End Users, 2019-2030
  • Figure 13.1: Global Infectious Disease Biomarker Testing Market (by Region), 2019 and 2030
  • Figure 13.2: Global Infectious Disease Biomarker Testing Market (by Region), 2019-2030
  • Figure 13.3: North America: Infectious Disease Biomarker Testing Market, 2019-2030
  • Figure 13.4: North America: Market Dynamics
  • Figure 13.5: North America: Infectious Disease Biomarker Testing Market (by Country), 2019 and 2030
  • Figure 13.6: U.S.: Infectious Disease Biomarker Testing Market, 2019-2030
  • Figure 13.7: Canada: Infectious Disease Biomarker Testing Market, 2019-2030
  • Figure 13.8: Europe: Infectious Disease Biomarker Testing Market, 2019-2030
  • Figure 13.9: Europe: Market Dynamics
  • Figure 13.10: Europe: Infectious Disease Biomarker Testing Market (by Country), 2019 and 2030
  • Figure 13.11: Germany: Infectious Disease Biomarker Testing Market, 2019-2030
  • Figure 13.12: U.K.: Infectious Disease Biomarker Testing Market, 2019-2030
  • Figure 13.13: France: Infectious Disease Biomarker Testing Market, 2019-2030
  • Figure 13.14: Italy: Infectious Disease Biomarker Testing Market, 2019-2030
  • Figure 13.15: Spain: Infectious Disease Biomarker Testing Market, 2019-2030
  • Figure 13.16: Switzerland: Infectious Disease Biomarker Testing Market, 2019-2030
  • Figure 13.17: Netherlands: Infectious Disease Biomarker Testing Market, 2019-2030
  • Figure 13.18: Rest-of-Europe: Infectious Disease Biomarker Testing Market, 2019-2030
  • Figure 13.19: Asia-Pacific: Infectious Disease Biomarker Testing Market, 2019-2030
  • Figure 13.20: Asia-Pacific: Market Dynamics
  • Figure 13.21: North America: Infectious Disease Biomarker Testing Market (by Country), 2019 and 2030
  • Figure 13.22: China: Infectious Disease Biomarker Testing Market, 2019-2030
  • Figure 13.23: Japan: Infectious Disease Biomarker Testing Market, 2019-2030
  • Figure 13.24: India: Infectious Disease Biomarker Testing Market, 2019-2030
  • Figure 13.25: Australia: Infectious Disease Biomarker Testing Market, 2019-2030
  • Figure 13.26: Singapore: Infectious Disease Biomarker Testing Market, 2019-2030
  • Figure 13.27: Singapore: Infectious Disease Biomarker Testing Market, 2019-2030
  • Figure 13.28: Rest-of-Asia-Pacific: Infectious Disease Biomarker Testing Market, 2019-2030
  • Figure 13.29: Rest-of-the-World: Infectious Disease Biomarker Testing Market, 2019-2030
  • Figure 13.30: Middle East and Africa: Market Dynamics
  • Figure 13.31: Rest-of-the-World: Infectious Disease Biomarker Testing Market (by Region), 2019 and 2030
  • Figure 13.32: Latin America: Infectious Disease Biomarker Testing Market, 2019-2030
  • Figure 13.33: Middle East and Africa: Infectious Disease Biomarker Testing Market, 2019-2030
  • Figure 14.1: Shares of Key Company Profiles
  • Figure 14.2: Abacus Diagnostica Oy: Product Portfolio for Global Infectious Disease Biomarker Testing Market
  • Figure 14.3: Abacus Diagnostica Oy: SWOT Analysis
  • Figure 14.4: Abbott Laboratories: Product Portfolio for Global Infectious Disease Biomarker Testing Market
  • Figure 14.5: Abbott Laboratories: Overall Financials, 2017-2019
  • Figure 14.6: Abbott Laboratories: Revenue (by Segment), 2017-2019
  • Figure 14.7: Abbott Laboratories: Revenue (by Region), 2017-2019
  • Figure 14.8: Abbott Laboratories: R&D Expenditure, 2017-2019
  • Figure 14.9: Abbott Laboratories: SWOT Analysis
  • Figure 14.10: Agilent Technologies, Inc.: Product Portfolio for the Global Infectious Disease Biomarker Testing Market
  • Figure 14.11: Agilent Technologies, Inc.: Overall Financials, 2017-2019
  • Figure 14.12: Agilent Technologies, Inc.: Revenue (by Segment), 2017-2019
  • Figure 14.13: Agilent Technologies, Inc.: Revenue (by Region), 2017-2019
  • Figure 14.14: Agilent Technologies, Inc.: R&D Expenditure, 2017-2019
  • Figure 14.15: Agilent Technologies, Inc.: SWOT Analysis
  • Figure 14.16: ALPCO: Product Portfolio for Global Infectious Disease Biomarker Testing Market
  • Figure 14.17: ALPCO: SWOT Analysis
  • Figure 14.18: Becton, Dickinson and Company: Product Portfolio for Global Infectious Disease Biomarker Testing Market
  • Figure 14.19: Becton, Dickinson and Company: Overall Financials, 2017-2019
  • Figure 14.20: Becton, Dickinson and Company: Revenue (by Segment), 2017-2019
  • Figure 14.21: Becton, Dickinson and Company: Revenue Split for BD Life Sciences, 2017-2019
  • Figure 14.22: Becton, Dickinson and Company: Revenue (by Region), 2017-2019
  • Figure 14.23: Becton, Dickinson and Company: R&D Expenditure, 2017-2019
  • Figure 14.24: Becton, Dickinson and Company: SWOT Analysis
  • Figure 14.25: bioMerieux SA: Product Portfolio for Global Infectious Disease Biomarker Testing Market
  • Figure 14.26: bioMerieux SA: Overall Financials, 2017-2019
  • Figure 14.27: bioMerieux SA: Revenue (by Segment), 2017-2019
  • Figure 14.28: bioMerieux SA: Revenue (by Region), 2017-2019
  • Figure 14.29: bioMerieux SA: R&D Expenditure, 2017-2019
  • Figure 14.30: bioMerieux SA: SWOT Analysis
  • Figure 14.31: Bio-Rad Laboratories, Inc.: Product Portfolio for Global Infectious Disease Biomarker Testing Market
  • Figure 14.32: Bio-Rad Laboratories, Inc.: Overall Financials, 2017-2019
  • Figure 14.33: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2017-2019
  • Figure 14.34: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2017-2019
  • Figure 14.35: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2017-2019
  • Figure 14.36: Bio-Rad Laboratories, Inc.: SWOT Analysis
  • Figure 14.37: Danaher Corporation: Product Portfolio for Global Infectious Disease Biomarker Testing Market
  • Figure 14.38: Danaher Corporation: Overall Financials, 2017-2019
  • Figure 14.39: Danaher Corporation: Revenue (by Business Segment), 2017-2019
  • Figure 14.40: Danaher Corporation: Revenue (by Region), 2017-2019
  • Figure 14.41: Danaher Corporation: R&D Expenditure (2017-2019)
  • Figure 14.42: Danaher Corporation: SWOT Analysis
  • Figure 14.43: F. Hoffmann-La Roche Ltd: Product Portfolio for Global Infectious Disease Biomarker Testing Market
  • Figure 14.44: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
  • Figure 14.45: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2017-2019
  • Figure 14.46: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019
  • Figure 14.47: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2017-2019
  • Figure 14.48: F. Hoffmann-La Roche Ltd: SWOT Analysis
  • Figure 14.49: Hologic, Inc.: Product Portfolio for Global Infectious Disease Biomarker Testing Market
  • Figure 14.50: Hologic, Inc.: Overall Financials, 2017-2019
  • Figure 14.51: Hologic, Inc.: Revenue (by Segment), 2017-2019
  • Figure 14.52: Hologic, Inc.: Revenue (by Region), 2017-2019
  • Figure 14.53: Hologic, Inc.: R&D Expenditure, 2017-2019
  • Figure 14.54: Hologic, Inc.: SWOT Analysis
  • Figure 14.55: PerkinElmer, Inc.: Product Portfolio for Global Infectious Disease Biomarker Testing Market
  • Figure 14.56: PerkinElmer, Inc.: Overall Financials, 2017-2019
  • Figure 14.57: PerkinElmer, Inc.: Revenue (by Segment), 2017-2019
  • Figure 14.58: PerkinElmer, Inc.: Revenue (by Region), 2017-2019
  • Figure 14.59: PerkinElmer, Inc.: R&D Expenditure, 2017-2019
  • Figure 14.60: PerkinElmer, Inc.: SWOT Analysis
  • Figure 14.61: QIAGEN N.V.: Product Portfolio for Global Infectious Disease Biomarker Testing Market
  • Figure 14.62: QIAGEN N.V.: Overall Financials, 2017-2019
  • Figure 14.63: QIAGEN N.V.: Revenue (by Segment), 2017-2019
  • Figure 14.64: QIAGEN N.V.: Revenue (by Region), 2017-2019
  • Figure 14.65: QIAGEN N.V.: R&D Expenditure, 2017-2019
  • Figure 14.66: QIAGEN N.V.: SWOT Analysis
  • Figure 14.67: Quest Diagnostics Incorporated: Product Portfolio for Global Infectious Disease Biomarker Testing Market
  • Figure 14.68: Quest Diagnostics Incorporated: Overall Financials, 2017-2019
  • Figure 14.69: Quest Diagnostics Incorporated.: Revenue (by Segment), 2017-2019
  • Figure 14.70: Quest Diagnostics Incorporated: SWOT Analysis
  • Figure 14.71: Siemens Healthineers AG: Product Portfolio for Global Infectious Disease Biomarker Testing Market
  • Figure 14.72: Siemens Healthineers AG: Overall Financials, 2017-2019
  • Figure 14.73: Siemens Healthineers AG: Revenue (by Segment), 2017-2019
  • Figure 14.74: Siemens Healthineers AG: Revenue (by Region), 2017-2019
  • Figure 14.75: Siemens Healthineers AG: R&D Expenditure, 2017-2019
  • Figure 14.76: Siemens Healthineers AG: SWOT Analysis
  • Figure 14.77: Thermo Fisher Scientific, Inc.: Product Portfolio for Global Infectious Disease Biomarker Testing Market
  • Figure 14.78: Thermo Fisher Scientific, Inc.: Overall Financials, 2017-2019
  • Figure 14.79: Thermo Fisher Scientific, Inc.: Revenue (by Business Segment), 2017-2019
  • Figure 14.80: Thermo Fisher Scientific, Inc.: Revenue (by Region), 2017-2019
  • Figure 14.81: Thermo Fisher Scientific, Inc.: R&D Expenditure (2017-2019)
  • Figure 14.82: Thermo Fisher Scientific, Inc.: SWOT Analysis